This week in charts: Biotech investors’ China bets are already paying off
BioPharma DiveBen FidlerNovember 20, 2026
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
